Publications by authors named "Patrizia Nanni"

Claim this Profile
D
Development of cellular models expressing cynomolgus () HER2 for the functional evaluation of cross-reactive anti-human HER2 response.
Chiara Cappello, Francesca Ruzzi, Julia Consoli, Maria Sofia Semprini, Laura Scalambra, Patrizia Nanni

Front Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Patrizia Nanni

J Transl Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay.
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Chiara Cappello, Patrizia Nanni

Methods Cell Biol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Patrizia Nanni

Cell Commun Signal· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Arianna Palladini, Stefania Angelicola, Patrizia Nanni

Int J Mol Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADK-VR2, a cell line derived from a treatment-naïve patient with fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, Elena Nironi, Maria Sofia Semprini, Patrizia Nanni

Transl Lung Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.
Veronica Giusti, Francesca Ruzzi, Lorena Landuzzi, Marianna L Ianzano, Roberta Laranga, Patrizia Nanni

Oncogenesis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy.
Carla De Giovanni, Lorena Landuzzi, Arianna Palladini, Giordano Nicoletti, Patrizia Nanni

Cells· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.
Lorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, Sofia Asioli, Giordano Nicoletti, Patrizia Nanni

Sci Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-γ and CD38 in Hyperprogressive Cancer Development.
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Patrizia Nanni

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.
Carla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Pier-Luigi Lollini, Patrizia Nanni

Cancers (Basel)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Patrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, Alberto Righi, Giordano Nicoletti

Sci Rep· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.
Carla De Giovanni, Lorena Landuzzi, Arianna Palladini, Marianna Lucia Ianzano, Giordano Nicoletti, Patrizia Nanni

Cancers (Basel)· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Lorenzo Castagnoli, Egidio Iorio, Matteo Dugo, Ada Koschorke, Simona Faraci, Patrizia Nanni

J Cell Physiol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.
Carla De Giovanni, Patrizia Nanni, Lorena Landuzzi, Marianna L Ianzano, Giordano Nicoletti

BMC Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.
Maria Cristina Manara, Sergio Valente, Camilla Cristalli, Giordano Nicoletti, Lorena Landuzzi, Patrizia Nanni

Mol Cancer Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
Valerio Leoni, Andrea Vannini, Valentina Gatta, Julie Rambaldi, Mara Sanapo, Patrizia Nanni

PLoS Pathog· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer immunoprevention: from mice to early clinical trials.
Arianna Palladini, Lorena Landuzzi, Pier-Luigi Lollini, Patrizia Nanni

BMC Immunol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.
Patrizia Nanni, Carla De Giovanni, Alessia Burocchi, Giordano Nicoletti, Lorena Landuzzi

Oncoimmunology· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-like particle display of HER2 induces potent anti-cancer responses.
Arianna Palladini, Susan Thrane, Christoph M Janitzek, Jessica Pihl, Stine B Clemmensen, Patrizia Nanni

Oncoimmunology· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.
Arianna Palladini, Giordano Nicoletti, Alessia Lamolinara, Massimiliano Dall'Ora, Tania Balboni, Patrizia Nanni

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Valerio Leoni, Valentina Gatta, Arianna Palladini, Giordano Nicoletti, Dario Ranieri, Patrizia Nanni

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Promise of Preventive Cancer Vaccines.
Pier-Luigi Lollini, Federica Cavallo, Patrizia Nanni, Elena Quaglino

Vaccines (Basel)· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Stefania Croci, Patrizia Nanni, Arianna Palladini, Giordano Nicoletti, Valentina Grosso

Breast Cancer Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.
Lorena Landuzzi, Marianna L Ianzano, Giordano Nicoletti, Arianna Palladini, Valentina Grosso, Patrizia Nanni

Oncotarget· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis